Navigation Links
Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
Date:1/16/2008

mmatory drug target. At the same time, they also protect cells and tissues against inflammatory damage. Morria is determined to become a pivotal player in the anti-inflammatory drug market by developing and commercializing novel drugs for acute pulmonary and gastro-intestinal inflammatory diseases. For more information, please visit http://www.morria.com.

This is not an invitation nor is it an offer to purchase or subscribe for shares. This release is only intended for persons falling within the exception set out in regulation 47 of the Financial Promotion order -- Persons in the business of disseminating information.

Contact:

Meghan Feeks

+1-212-827-0020

mfeeks@rlcinc.com


'/>"/>
SOURCE Morria Biopharmaceuticals Plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
2. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
3. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
4. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
5. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
8. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
9. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
10. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014 STAAR Surgical Company (NASDAQ: ... implantable lenses and delivery systems for the eye today ... 2014 of $20.0 million, a 10% increase over $18.2 ... a constant currency basis, revenues grew 11% during the ... of 2013.  The effect of foreign currency exchange reduced ...
(Date:7/31/2014)... SAN DIEGO, July 31, 2014  ResMed Inc. (NYSE: ... and for the fiscal year ended June 30, 2014.  Revenue ... quarter ended June 30, 2013 (a 1 percent decrease on ... increase of 20 percent compared to the quarter ended June ... $0.61, an increase of 22 percent compared to the quarter ...
(Date:7/31/2014)... -- Xencor Inc. (NASDAQ: XNCR ), ... for the treatment of autoimmune diseases, asthma and ... for the second quarter ended June 30, 2014 and ... "In the second quarter, we presented preclinical ... Conference (ATS) demonstrating three novel mechanisms of action ...
Breaking Medicine Technology:STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6
(Date:7/31/2014)... July 31, 2014 (HealthDay News) -- Transplant surgeons ... red flags for burnout, a new study suggests. ... the study reported having a low sense of ... to feeling emotionally exhausted, researchers found. "Burnout ... like transplantation," study co-author Dr. Marwan Abouljoud, director ...
(Date:7/31/2014)... Scientists have learned that recent fears of invasive lionfish ... efforts to control lionfish by fishing derbies and targeted ... invasion. And there,s a simple way to know for ... after it,s been cooked. , Pacific lionfish were first ... and have been gaining swiftly in number ever since. ...
(Date:7/31/2014)... July 31, 2014 Millions of people ... have had traumatic experiences as a child and some ... work. As a highly experienced NJ cosmetic dentist, ... anxiety during their dental procedure. To help these ... team at Champagne Smiles offer several sedation dentistry techniques. ...
(Date:7/31/2014)... Scotch Plains, New Jersey (PRWEB) July 31, 2014 ... certified dermatologist by the American Board of Dermatology, fellowship ... approved again by NJ Top Docs. , After extensive ... the National Institutes of Health, Dr. Li completed his ... dermatology training at the University of Pennsylvania in Philadelphia. ...
(Date:7/31/2014)... York (PRWEB) July 31, 2014 ... as Bernstein Liebhard LLP notes that Johnson & ... plans to voluntarily remove its power morcellators ( ... report from Bloomberg.com, the company said it decided ... associated with the devices remain uncertain.* , “In ...
Breaking Medicine News(10 mins):Health News:Burnout Common Among Transplant Surgeons, Study Reveals 2Health News:Invasive lionfish likely safe to eat after all 2Health News:Invasive lionfish likely safe to eat after all 3Health News:Champagne Smiles is Thrilled to Now Offer Sedation Dentistry to their Patients 2Health News:NJ Top Docs Proudly Presents Approved Provider, Dr. Andrew Li of Warren Skin Care Center 2Health News:Uterine Morcellation Controversy Grows, as Bernstein Liebhard LLP Notes Johnson & Johnson Decision to Withdraw Power Morcellators from Market 2Health News:Uterine Morcellation Controversy Grows, as Bernstein Liebhard LLP Notes Johnson & Johnson Decision to Withdraw Power Morcellators from Market 3
... Goodwin HealthDay Reporter , THURSDAY, May 10 ... children have little or no label information about drug ... "We still have a long way to go," ... of the U.S. Food and Drug Administration,s Office of ...
... , THURSDAY, May 10 (HealthDay News) -- A ... U.S. Food and Drug Administration showed promising results in ... took Qnexa, a combination of the drugs phentermine and ... many weight-related health problems, the study found. The findings ...
... a low haemoglobin (Hb) level do not respond well to ... survival are compromised. Now researchers from The Netherlands have found ... can be overcome by the use of a treatment known ... carbogen (a mixture of carbon dioxide and oxygen) and the ...
... privately insured colon cancer patients found that managed care presence ... surgery to treat colon cancer lowered costs, a national team ... University School of Public Health and Health Services reported in ... cancer is the second leading cause of cancer death in ...
... 2012) A review of 30 years of life-threatening asthma ... annual ICU admissions for the condition have dropped 74 percent. ... cases at University Hospital between 1980 and 2010, also showed ... not result in longer hospital stays. UT Medicine is ...
... severe complications from systemic sclerosis, also known as scleroderma, ... Rheumatism , a journal of the American College of ... were more likely to have antibodies that increased frequency ... decreased survival. According to the ACR there ...
Cached Medicine News:Health News:Only Half of Meds Taken by Kids Have 'Adequate' Safety Info: Study 2Health News:Only Half of Meds Taken by Kids Have 'Adequate' Safety Info: Study 3Health News:New Weight-Loss Drug Shows Promise in Trial 2Health News:New Weight-Loss Drug Shows Promise in Trial 3Health News:Researchers discover how to overcome poor response to radiotherapy caused by low haemoglobin levels 2Health News:Researchers discover how to overcome poor response to radiotherapy caused by low haemoglobin levels 3Health News:Economic theory actually works in health care 2Health News:ICU stays for worst asthma drop 74 percent, review finds 2Health News:Systemic sclerosis complications more severe in African Americans than Caucasians 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: